NCT06574984

Study for Turoctocog Alfa Treatment Regimen in Iraqi Haemophilia A Patients

Descriptive Study for Turoctocog Alfa Treatment Regimen in Iraqi Haemophilia A Patients - An Observational Retrospective Study

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 900 (estimated)
• Sponsor: Novo Nordisk A/S · Industry
• Sex: Male
• Age: —
• Healthy volunteers: Not accepted

Summary

The study has descriptive purposes, with aim of assessing how turoctocog alfa is used in the everyday practice and to provide a baseline for the management of haemophilia A and does not involve any change in the clinical management of participants. Data will be extrapolated from the existing paper based medical records and uploaded to an electronic database specifically created for the study. Baseline information/history will be recorded at time of switching from previous FVIII replacement therapy to turoctocog alfa from the enrolled participants and outcomes will be collected according to participants visit format.

Conditions

• Congenital Bleeding Disorder
• Haemophilia A

Interventions

Type	Name	Description
DRUG	Turoctocog alfa	Turoctocog alfa was administered intravenously.

Timeline

• Start date: 2024-11-10
• Primary completion: 2026-02-27
• Completion: 2026-04-30
• First posted: 2024-08-28
• Last updated: 2026-02-13

Locations

7 sites across 1 country: Iraq